Ms. Henson was appointed to the Lisata Board in September 2022. Heidi joins the Board with over two decades of financial operations experience with both public and private companies. She currently serves as the Chief Financial Officer at Pardes Biosciences where she was instrumental in completing their de-SPAC transaction. Before Pardes, she served as the Chief Financial Officer for Imbria Pharmaceuticals, Kura Oncology, Intellikine (acquired by Takeda), Wellspring Biosciences, and their parent company, Araxes Pharma.
Heidi has guided numerous companies through early-stage start-up activities, SEC reporting, and Sarbanes-Oxley implementation and compliance. She began her career as an auditor with PricewaterhouseCoopers. She currently also serves on the board of directors of PepGen Inc. She holds a BS in Accounting from the University of San Diego and is a Certified Public Accountant (currently inactive) in California.